Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
1998-07-24
2003-08-26
Baker, Anne-Marie (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C424S093200, C424S450000, C536S023100
Reexamination Certificate
active
06610532
ABSTRACT:
TECHNICAL FIELD
The present invention relates, in general, to myocardial hypertrophy and, in particular, to agents that inhibit cardiac Gq-coupled receptor signaling and to methods of inhibiting myocardial hypertrophy using same.
BACKGROUND
Myocardial hypertrophy is an adaptive response to a variety of mechanical and hormonal stimuli and represents an initial step in the pathogenesis of many cardiac diseases which ultimately progress to ventricular failure. Due to the high mortality associated with heart failure, there is strong interest in identifying regulatory molecular determinants which lead to myocardial hypertrophy and subsequently to the transition to failure. Several disease conditions can trigger the non-failing ventricle to develop increased wall thickness as an initial compensatory mechanism to meet the heightened demands placed on the pump. In man, this situation can arise in some cardiovascular disease states including hypertension. The mechanisms by which cardiac hypertrophy is initiated and how this condition eventually progresses to heart failure are poorly understood.
The heart is unique in that it is composed of terminally differentiated myocytes which respond to hypertrophic stimuli by increasing in size rather than number (Chien et al, FASEB J. 5:3037 (1991)). Utilizing cultured neonatal cardiac myocytes, several independent signaling pathways have been implicated in the activation of the hypertrophic response in vitro (Chien et al. FASEB J. 5:3037 (1991). The hypertrophy seen in vitro involves an increase in cellular size and volume, differential expression of various contractile proteins, and reactivation of an embryonic gene program which includes ventricular induction of atrial natriuretic factor (ANF), skeletal a-actin, and b-myosin heavy chain. Candidate signaling molecules for the initiation of hypertrophy have been identified including p21
ras
(ras) (Thorburn et al, J. Biol. Chem. 268:2244 (1993)), although hypertrophy of myocytes in vitro can also occur in a ras-independent manner (LaMorte et al, J. Biol. Chem. 269:13490(1994)). The heterotrimeric guanine nucleotide binding (G) protein, Gq, is thought to be important in this process since various ligands (i.e. phenylephrine, angiotensin II, and endothelin I) that activate Gq-coupled receptor molecules can trigger hypertrophic responses in cultured myocytes (Sadoshima et al, Cell 95:977 (1993), Simpson, J. Clin. Invest. 72:732 (1983); Shubeita et al, J. Biol. Chem. 265:20555 (1990)).
Receptors that stimulate Gq are members of the G protein-coupled receptor family which share conserved seven transmembrane topography. The binding of agonists induces conformational changes in the receptor molecule which cause its intracellular domains to interact with the carboxyl terminal portion of the a-subunit of G proteins (Neer et al, Cell 80:249 (1995)). It has been previously reported that cellular expression of the third intracellular domain (3i) of the a
1B
-adrenergic receptor (AR) in vitro antagonizes a
1B
-AR-mediated signal transduction, apparently through competition between the 3i peptide and the activated receptor for binding sites on Gaq (Luttrell et al, Science 259:1453 (1993)). Other in vitro studies have demonstrated that peptides derived from the carboxyl terminus of Gas (Palm et al. FEBS Lett. 261:294 (1990)) and Gai
2
(Okamato et al, J. Biol. Chem. 269:13756 (1994)) can block in vitro receptor-mediated G protein signaling.
The present invention results from studies demonstrating, in vivo, the importance of myocardial Gq-coupled signaling in the initiation of ventricular hypertrophy. This demonstration makes possible novel therapeutic strategies for preventing hypertrophy and the transition to heart failure.
SUMMARY OF THE INVENTION
The present invention relates to agents that inhibit cardiac Gq-coupled receptor signaling. The invention further relates to a method of inhibiting maladaptive ventricular hypertrophy associated with various forms of cardiac disease in transition to failure, which method utilizes such agents. The invention further relates to a method of inhibiting vascular smooth muscle proliferation and migration, which method also utilizes inhibitors of Gq-coupled receptor signaling.
Objects and advantages of the invention will be clear from the description that follows.
REFERENCES:
patent: 5082779 (1992-01-01), Rottman et al.
patent: 5175383 (1992-12-01), Leder
patent: 5175384 (1992-12-01), Krimpenfort
patent: 5175385 (1992-12-01), Wagner et al.
patent: 5624936 (1997-04-01), deSolms
patent: 5981487 (1999-11-01), Koch
patent: 0 351 921 (1990-01-01), None
patent: 0 453 119 (1991-10-01), None
patent: WO 92/07070 (1992-04-01), None
Friedmann, T. Overcoming the obstacles to gene therapy. Sci. Am. Jun. 1997, pp. 96-101.*
Orkin and Motulsky. Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Dec. 1995.*
Verma et al. Gene therapy—promises, problems and prospects. Nature 389: 239-242, Sep. 1997.*
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success”, Science 270:404-410 (1995).
Marshall, “Less Hype, More Biology Needed for Gene Therapy”, Science 270:1751 (1995).
Coghlan, “Gene dream fades away”, New Scientist 148:14-15 (1995).
Günsburg et al, “Virus vector design in gene therapy”, Molecular Medicine Today pp. 410-417 (1995).
Foecking et al, “Powerful and versatile enhancer-promoter unit for mammalian expression vectors”, Gene 45:101-105 (1986).
Koch et al, “Cellular Expression of the Carboxyl Terminus of a G Protein-coupled Receptor Kinase Attenuates G&bgr;&ggr;-mediated Signaling”, J. Biological Chem. 269:6193-6197 (1994).
Lee et al, “Cardiac and Pulmonary Replacement”, J. Thoracic Cardiovascular Surgery 111(1):246-252 (1996).
Fuller et al, “Genetic Engineering of Cardiac Muscle Cells: In Vitro and In Vivo”, Genetic Engineering 16:17-27 (1994).
Luckow et al, “CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements”, Nucleic Acids Research 15(13):5490 (1987).
Ngo et al, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, K. Merz, Jr. and S. Le Grand, Editors, Birkhauser Bost Inc., pp. 491-495 (1994).
Dillon, “Regulating gene expression in gene therapy”, TibTech 11:167-173 (1993).
Rigby, “Gene therapy: a long and winding road”, Current Opinion in Genetics and Development 5:397-398 (1995).
Orkin et al, “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, pp. 1-50, Dec. 7, 1995.
Benovic et al, “cDNA Cloning and Chromosomal Localization of the Human &bgr;-Adrenergic Receptor Kinase”, FEBS 283(1):122-126 (1991).
Bertin et al, “Atrial Overexpression of B1-AR in Transgenic Mice. A New Potential Pharmacological Model”, Cardiovascular Drugs and Therapy 7 (Suppl. 2):465 (1993).
Gaudin et al, Overexpression of Gs&agr; Protein the Haeart of Transgenic Mice, Clinical Res. 41(2):145a (1993).
Schmidt et al, “The Cytomegalovirus Enhancer: a Pan-Active Control Element in Transgenic Mice”, Molecular and Cellular Biology 10:4406-4411 (1990).
Touhara et al, “Mutational Analysis of the Pleckstrin Homology Domain of the &bgr;-Adrenergic Receptor Kinase”, The Journal of Biological Chemistry 270(28):17000-17005 (1995).
Milano et al, “Enhanced Myocardial Function in Transgenic Mice Overexpressing the &bgr;2-Adrenergic Receptor”, Science 264:582-586 (1994).
Seachrist, L., “Gene Transfer to Spark a Failing Heart”, Science 264:507-508 (1994).
Koch et al, “Cardiac Function in Mice Overexpressing the &bgr;-Adrenergic Receptor Kinase or a &bgr;ARK Inhibitor”, Science 268:1350-1353 (1995).
Kaufman, Randal J., “Expression of Proteins in Mammalian Cells”, Current Protocols in Molecular Biology, Supplement 14, Section III, Unit 16.12.1-16.12.6 (1994).
Aruffo, A., “Transient Expression of Proteins Using COS Cells”, Current Protocols in Molecular Biology, Supplemental 14, Section III, Unit 16.13.1-16.13.7 (1991).
Subramaniam et al, “T
Akhter Shahab A.
Koch Walter J.
Lefkowitz Robert J.
Luttrell Louis M.
Rockman Howard
Baker Anne-Marie
Duke University
Nixon & Vanderhye P.C.
LandOfFree
Intracellular inhibitors of Gq protein signaling does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intracellular inhibitors of Gq protein signaling, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intracellular inhibitors of Gq protein signaling will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3085195